analyst
SG
NASDAQ · SGMT
Sagimet Biosciences Inc.
Healthcare · Biotechnology
$10.46
Down-$0.42 (-3.86%)
Updated Sep 16, 2026, 7:17 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 196.86M
- P/E ratio
- -3.57
- Dividend yield
- 0.00%
- 52-week range
- $4.50 – $11.45
- Volume
- 852.73K
- Avg. volume
- 561.82K
Price performance
SGMT price history
1M range · 20 trading sessions · Daily adjusted prices
SGMT closed at $10.46 after 20 trading sessions, down 1.13% for the selected period.
- Last close
- $10.46
- Period change
- -1.13%
- Period low
- $10.18
- Period high
- $11.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $10.805 | $10.84 | $10.31 | $10.46 | 852.73K |
| Sep 14, 2026 | $10.96 | $11.095 | $10.82 | $10.88 | 516.76K |
| Sep 11, 2026 | $11.33 | $11.35 | $10.77 | $10.88 | 639.39K |
| Sep 10, 2026 | $10.75 | $11.449 | $10.67 | $11.06 | 937.7K |
| Sep 9, 2026 | $11.25 | $11.27 | $10.685 | $10.86 | 1.25M |
| Sep 8, 2026 | $10.84 | $11.17 | $10.65 | $10.71 | 805.61K |
| Sep 4, 2026 | $10.79 | $10.98 | $10.53 | $10.94 | 1.25M |
| Sep 3, 2026 | $11.205 | $11.24 | $10.62 | $10.92 | 1.14M |
| Sep 2, 2026 | $10.51 | $11.06 | $10.51 | $10.99 | 1.8M |
| Sep 1, 2026 | $10.15 | $10.72 | $10.15 | $10.50 | 752.2K |
| Aug 31, 2026 | $10.36 | $10.435 | $10.21 | $10.26 | 688.44K |
| Aug 28, 2026 | $10.62 | $10.81 | $10.47 | $10.55 | 574K |
| Aug 27, 2026 | $10.90 | $10.95 | $10.54 | $10.75 | 657.68K |
| Aug 26, 2026 | $10.26 | $10.87 | $10.105 | $10.86 | 1.24M |
| Aug 25, 2026 | $10.38 | $10.60 | $10.20 | $10.29 | 968.56K |
| Aug 24, 2026 | $10.13 | $10.505 | $9.95 | $10.21 | 1.24M |
| Aug 21, 2026 | $10.22 | $10.48 | $10.055 | $10.25 | 1.02M |
| Aug 20, 2026 | $10.48 | $10.635 | $10.15 | $10.18 | 1.14M |
| Aug 19, 2026 | $10.80 | $11.03 | $10.49 | $10.58 | 1.55M |
| Aug 18, 2026 | $10.41 | $10.74 | $10.375 | $10.58 | 980.52K |
Latest SGMT news
The latest Smart Investors Daily articles mentioning SGMT.
Stock researchCompany · Overview
SGMT research
Overview
Company profile and research snapshot.
Company profile
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $6.00
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Barclays | Overweight | — |
| Sep 9, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 14, 2026 | Citizens | Market Outperform | — |
| Aug 12, 2026 | Canaccord Genuity | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.